Health

A recent interim analysis of the phase III ECHELON-3 trial revealed that a triplet combination of brentuximab vedotin (BV), lenalidomide, and rituximab showed a significant improvement in overall survival for patients with diffuse large B-cell lymphoma (DLBCL). The study, conducted by Jeong-A Kim, MD, at the American Society of Clinical Oncology meeting, demonstrated a 37%
0 Comments
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a challenging condition to diagnose due to its rarity and heterogeneity. Dr. Jeffrey Allen from the University of Minnesota emphasized the critical need for valid biomarkers in CIDP to improve diagnosis and understand disease activity. The current standard treatments for CIDP, including intravenous immunoglobulin (IVIG), steroids, and plasma exchange,
0 Comments
The Food and Drug Administration (FDA) recently issued a warning to Akan Biosciences, a Maryland-based company, regarding their allogenic, adipose-derived stromal vascular fraction (SVF) product, known as Ayama. This warning highlighted the fact that the product must be regulated as a drug and a biologic, as opposed to the more lenient category it was previously
0 Comments
The journey towards democratizing knowledge and expertise has been a long and evolving one. It all began 600 years ago with the groundbreaking invention of the printing press by Johannes Gutenberg in Mainz, Germany. This invention revolutionized the way information was shared, breaking down barriers that had previously made knowledge accessible only to the privileged
0 Comments
The recent statement by the CDC regarding the potential increased risk of the H5N1 virus to human health has sparked concerns about a possible pandemic. While the current risk remains low, the agency is gearing up for the possibility that the influenza A(H5N1) viruses could mutate and become easily transmissible among humans, leading to a
0 Comments